Citigroup Inc. Lowers Gilead Sciences, Inc. (GILD) to Neutral

Citigroup Inc. Lowers Gilead Sciences, Inc. (GILD) to Neutral


They presently have a $76.00 price target on the biopharmaceutical company's stock, down from their previous price target of $87.00. Citigroup Inc.'s target price indicates a potential upside of 14.53% from the stock's current price.



from Biotech News